Aerie pharmaceuticals announces appointment of leon j. atencia, director of regulatory affairs

Durham, n.c.--(business wire)--aerie pharmaceuticals, inc. (nasdaq:aeri), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced the appointment of leon j. atencia, director of regulatory affairs, reporting to emma beausang, aerie's vice president of regulatory affairs. mr. atencia will be responsible for clini
AERI Ratings Summary
AERI Quant Ranking